Epstein Secrets

• Twenty NATO Members Not Forecast To Meet 2% Of GDP Defense Spending Target By 2024. • Putin Hints At Russia-China Military Alliance. • Hopes For Armenia-Azerbaijan Deal Fade Despite Upcoming Pompeo Meeting. • Sudanese Government Prepared To Normalize Relations With Israel As Part Of US Deal. • Harir

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

• Twenty NATO Members Not Forecast To Meet 2% Of GDP Defense Spending Target By 2024. • Putin Hints At Russia-China Military Alliance. • Hopes For Armenia-Azerbaijan Deal Fade Despite Upcoming Pompeo Meeting. • Sudanese Government Prepared To Normalize Relations With Israel As Part Of US Deal. • Harir

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

• Twenty NATO Members Not Forecast To Meet 2% Of GDP Defense Spending Target By 2024. • Putin Hints At Russia-China Military Alliance. • Hopes For Armenia-Azerbaijan Deal Fade Despite Upcoming Pompeo Meeting. • Sudanese Government Prepared To Normalize Relations With Israel As Part Of US Deal. • Harir

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug